MNPR vs. SMR

Last updated Jun 4, 2026

MNPR (Monopar Therapeutics Inc.) and SMR (Nuscale Power Corp) are both stocks. MNPR operates in Biotechnology (Healthcare), while SMR operates in Specialty Industrial Machinery (Industrials). Over the past 5 years, MNPR returned 15.47%/yr vs 4.24%/yr for SMR. At a 0.10 correlation, their price movements are largely independent.

Performance

MNPR vs. SMR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Monopar Therapeutics Inc. (MNPR) and Nuscale Power Corp (SMR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MNPR achieves a -7.26% return, which is significantly higher than SMR's -13.41% return.

MNPR

• 1D: -1.14%
• 1M: 10.83%
• YTD: -7.26%
• 6M: -21.54%
• 1Y: 88.60%
• 3Y*: 130.42%
• 5Y*: 15.47%
• 10Y*: —

SMR

• 1D: -12.04%
• 1M: 0.74%
• YTD: -13.41%
• 6M: -39.08%
• 1Y: -61.40%
• 3Y*: 16.95%
• 5Y*: 4.24%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

MNPR vs. SMR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
MNPR Monopar Therapeutics Inc.	-7.26%	196.82%	1,193.36%	-85.65%	-26.17%	-47.55%	8.13%
SMR Nuscale Power Corp	-13.41%	-20.97%	444.98%	-67.93%	2.29%	-0.89%	1.71%

Correlation

The correlation between MNPR and SMR is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.13
Correlation (5Y) Calculated over the trailing 5-year period	0.10
Correlation (All Time) Calculated using the full available price history since Dec 10, 2020	0.10

The correlation between MNPR and SMR shifts across timeframes, from 0.10 (5 years) to 0.20 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap MNPR : $516.88M SMR : $3.92B
EPS MNPR : -$532.10 SMR : -$2.02
PB Ratio MNPR : 0.00 SMR : 3.36
Total Revenue (TTM) MNPR : $0.00 SMR : $18.10M
Gross Profit (TTM) MNPR : $0.00 SMR : $4.45M
EBITDA (TTM) MNPR : -$5.24B SMR : -$696.20M

Return for Risk

MNPR vs. SMR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MNPR

MNPR Risk / Return Rank: 71
MNPR Sharpe Ratio Rank: 74
MNPR Sortino Ratio Rank: 75
MNPR Omega Ratio Rank: 70
MNPR Calmar Ratio Rank: 72
MNPR Martin Ratio Rank: 66

SMR

SMR Risk / Return Rank: 16
SMR Sharpe Ratio Rank: 15
SMR Sortino Ratio Rank: 17
SMR Omega Ratio Rank: 19
SMR Calmar Ratio Rank: 13
SMR Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MNPR vs. SMR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Monopar Therapeutics Inc. (MNPR) and Nuscale Power Corp (SMR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MNPR	SMR	Difference
Sharpe ratio: Return per unit of total volatility	1.11	-0.59	+1.70
Sortino ratio: Return per unit of downside risk	2.00	-0.61	+2.61
Omega ratio: Gain probability vs. loss probability	1.23	0.94	+0.30
Calmar ratio: Return relative to maximum drawdown	1.75	-0.74	+2.49
Martin ratio: Return relative to average drawdown	2.91	-1.10	+4.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MNPR vs. SMR - Sharpe Ratio Comparison

The current MNPR Sharpe Ratio is 1.11, which is higher than the SMR Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of MNPR and SMR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MNPR	SMR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.11	-0.59	+1.70
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.05	0.05	+0.01
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	0.04	-0.09

Drawdowns

MNPR vs. SMR - Drawdown Comparison

The maximum MNPR drawdown since its inception was -98.93%, which is greater than SMR's maximum drawdown of -87.47%. Use the drawdown chart below to compare losses from any high point for MNPR and SMR.

Drawdown Indicators

	MNPR	SMR	Difference
Max Drawdown Largest peak-to-trough decline	-98.93%	-87.47%	-11.46%
Max Drawdown (1Y) Largest decline over 1 year	-50.89%	-82.86%	+31.97%
Max Drawdown (3Y) Largest decline over 3 years	-71.07%	-82.86%	+11.79%
Max Drawdown (5Y) Largest decline over 5 years	-95.54%	-87.47%	-8.07%
Current Drawdown Current decline from peak	-55.14%	-77.04%	+21.90%
Average Drawdown Average peak-to-trough decline	-80.41%	-34.87%	-45.54%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.53%	55.79%	-25.26%

Volatility

MNPR vs. SMR - Volatility Comparison

The current volatility for Monopar Therapeutics Inc. (MNPR) is 24.28%, while Nuscale Power Corp (SMR) has a volatility of 30.10%. This indicates that MNPR experiences smaller price fluctuations and is considered to be less risky than SMR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MNPR	SMR	Difference
Volatility (1M) Calculated over the trailing 1-month period	24.28%	30.10%	-5.82%
Volatility (6M) Calculated over the trailing 6-month period	43.75%	69.57%	-25.82%
Volatility (1Y) Calculated over the trailing 1-year period	80.78%	103.97%	-23.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	295.98%	93.22%	+202.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	264.98%	89.27%	+175.71%

Dividends

MNPR vs. SMR - Dividend Comparison

Neither MNPR nor SMR has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MNPR and SMR in my portfolio?

MNPR and SMR have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MNPR or SMR?

SMR has higher volatility (30.10%) compared to MNPR (24.28%). In terms of maximum drawdown, MNPR dropped -98.93% vs SMR's -87.47%.

Which has better risk-adjusted returns?

MNPR currently has the higher Sharpe Ratio (1.11 vs -0.59), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.